Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats.

Ilijana BabicAshleigh GorakMartin EngelDominic SellersPaul ElseAshleigh L OsborneNagesh PaiXu-Feng HuangJessica NealonKatrina Weston-Green

Published in: Journal of psychopharmacology (Oxford, England) (2018)

Liraglutide co-treatment improved aspects of cognition, prevented obesity side-effects of olanzapine, and the hyperglycaemia caused by clozapine, when administered from the start of APD treatment. The results demonstrate a potential treatment for individuals at a high risk of experiencing adverse effects of APDs.

Keyphrases

working memory
metabolic syndrome
combination therapy
risk assessment
body mass index
mouse model
mild cognitive impairment
adverse drug